[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ES2099438T3 - Polvo seco y estable de cefalosporina hidratada para formulacion de suspension oral. - Google Patents

Polvo seco y estable de cefalosporina hidratada para formulacion de suspension oral.

Info

Publication number
ES2099438T3
ES2099438T3 ES93910771T ES93910771T ES2099438T3 ES 2099438 T3 ES2099438 T3 ES 2099438T3 ES 93910771 T ES93910771 T ES 93910771T ES 93910771 T ES93910771 T ES 93910771T ES 2099438 T3 ES2099438 T3 ES 2099438T3
Authority
ES
Spain
Prior art keywords
dry
pct
oral suspension
suspension formulation
stable powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93910771T
Other languages
English (en)
Inventor
Donald A Johnson
Lorraine Wearley
Rebecca Galeos
Joel A Sequeira
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ES2099438T3 publication Critical patent/ES2099438T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)

Abstract

SE DESCRIBEN UNA CEFALOSPORINA HIDRATADA SECA, POR EJEMPLO, CEFTIBUTENO, TENIENDO ENTRE EL 7 Y EL 14% POR PESO DE AGUA, FORMULACION DE POLVO, COMPOSICIONES FARMACEUTICAS EN FORMA DE UNA FORMA DE DOSIFICACION DE SUSPENSION ORAL, Y UN METODO PARA OBTENER LAS FORMULACIONES DE POLVO SECO.
ES93910771T 1992-04-30 1993-04-30 Polvo seco y estable de cefalosporina hidratada para formulacion de suspension oral. Expired - Lifetime ES2099438T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US87688192A 1992-04-30 1992-04-30

Publications (1)

Publication Number Publication Date
ES2099438T3 true ES2099438T3 (es) 1997-05-16

Family

ID=25368763

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93910771T Expired - Lifetime ES2099438T3 (es) 1992-04-30 1993-04-30 Polvo seco y estable de cefalosporina hidratada para formulacion de suspension oral.

Country Status (23)

Country Link
US (1) US5599557A (es)
EP (1) EP0642344B1 (es)
JP (1) JP3378004B2 (es)
KR (1) KR100257803B1 (es)
AT (1) ATE150310T1 (es)
AU (1) AU674516B2 (es)
CA (1) CA2134467A1 (es)
CZ (1) CZ283428B6 (es)
DE (1) DE69309052T2 (es)
DK (1) DK0642344T3 (es)
EE (1) EE03039B1 (es)
ES (1) ES2099438T3 (es)
FI (1) FI945081A (es)
GR (1) GR3023516T3 (es)
HK (1) HK1002407A1 (es)
HU (1) HU215958B (es)
NO (1) NO307594B1 (es)
NZ (1) NZ252433A (es)
PL (1) PL171630B1 (es)
RU (1) RU2123863C1 (es)
SK (1) SK279329B6 (es)
UA (1) UA27899C2 (es)
WO (1) WO1993021923A1 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2079327B1 (es) * 1994-12-13 1996-08-01 Lilly Sa Formulaciones farmaceuticas de cefaclor.
US6565882B2 (en) * 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6541014B2 (en) * 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
US20020068078A1 (en) * 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US20020197314A1 (en) * 2001-02-23 2002-12-26 Rudnic Edward M. Anti-fungal composition
US7101573B2 (en) * 2001-09-28 2006-09-05 Mcneil-Pcc, Inc. Simethicone solid oral dosage form
AU2004258949B2 (en) * 2003-07-21 2011-02-10 Shionogi, Inc. Antibiotic product, use and formulation thereof
AU2004258944B2 (en) * 2003-07-21 2011-02-10 Shionogi, Inc. Antibiotic product, use and formulation thereof
US8313775B2 (en) * 2003-07-21 2012-11-20 Shionogi Inc. Antibiotic product, use and formulation thereof
EP1653925A1 (en) * 2003-08-11 2006-05-10 Advancis Pharmaceutical Corporation Robust pellet
US8062672B2 (en) * 2003-08-12 2011-11-22 Shionogi Inc. Antibiotic product, use and formulation thereof
US8246996B2 (en) * 2003-08-29 2012-08-21 Shionogi Inc. Antibiotic product, use and formulation thereof
EP1663169A4 (en) * 2003-09-15 2010-11-24 Middlebrook Pharmaceuticals In ANTIBIOTICS, ITS USE AND FORMULATION
EP1701705A4 (en) * 2003-12-24 2007-08-08 Advancis Pharmaceutical Corp IMPROVED ABSORPTION OF MODIFIED RELEASE DOSAGE FORMS
US8715727B2 (en) * 2004-07-02 2014-05-06 Shionogi Inc. Tablet for pulsed delivery
US8653145B2 (en) * 2005-09-22 2014-02-18 Eaton Scientific Systems, Ltd. Method for alleviating climacteric symptoms
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US8778924B2 (en) * 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
US20100048609A1 (en) * 2006-08-01 2010-02-25 Jacobs Jeffrey W Pharmaceutical dosage forms for (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid
FR2911506B1 (fr) * 2007-01-18 2009-07-03 Ceva Sante Animale Sa Compositions pharmaceutiques destinees a une administration par voie orale sous forme de suspensions aqueuses stabilisees
US8999395B2 (en) 2007-02-09 2015-04-07 Ceva Sante Animale Pharmaceutical compositions for oral administration in the form of stabilised aqueous suspensions
TW200918096A (en) * 2007-06-22 2009-05-01 Kaneka Corp Composition comprising bioactive substance
JP5364580B2 (ja) * 2007-08-22 2013-12-11 株式会社カネカ 還元型補酵素ｑ１０の製造方法、ならびに、その安定化方法
EP2566449B1 (en) * 2010-05-04 2014-10-08 Mahmut Bilgic Pharmaceutical compositions comprising ceftibuten
RU2550932C1 (ru) * 2014-03-18 2015-05-20 Александр Александрович Кролевец Способ получения нанокапсул цефалоспориновых антибиотиков в ксантановой камеди

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3549746A (en) * 1967-11-02 1970-12-22 Bristol Myers Co Antibiotic composition
US3780195A (en) * 1969-10-22 1973-12-18 Balchem Corp Encapsulation process
US4016254A (en) * 1972-05-19 1977-04-05 Beecham Group Limited Pharmaceutical formulations
GB1561301A (en) * 1976-01-02 1980-02-20 Beecham Group Ltd Orally administrable pharmaceutical composition
US4321253A (en) * 1980-08-22 1982-03-23 Beatty Morgan L Suspension of microencapsulated bacampicillin acid addition salt for oral, especially pediatric, administration
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
IT1183574B (it) * 1985-05-08 1987-10-22 Eurand Spa Metodo per ottenere una sospensione estemporanea omogenea di microcapsule
NZ220764A (en) * 1986-07-02 1989-09-27 Shionogi & Co Crystalline form of 7beta((z)-2-(2-aminothiazol-4-yl)-4- carboxybut-2-enoylamino)-3-cephem-4-carboxylic acid and pharmaceutical compositions
US4803082A (en) * 1987-10-28 1989-02-07 Warner-Lambert Company Flavor and sweetness enhancement delivery systems and method of preparation
US5112604A (en) * 1989-09-01 1992-05-12 Riker Laboratories, Inc. Oral suspension formulation

Also Published As

Publication number Publication date
KR100257803B1 (en) 2000-08-01
PL171630B1 (pl) 1997-05-30
DE69309052T2 (de) 1997-06-19
EE03039B1 (et) 1997-10-15
JP3378004B2 (ja) 2003-02-17
KR950701224A (ko) 1995-03-23
RU94046038A (ru) 1996-11-10
SK131194A3 (en) 1995-07-11
SK279329B6 (sk) 1998-10-07
EP0642344B1 (en) 1997-03-19
NO944113D0 (no) 1994-10-28
HUT71226A (en) 1995-11-28
EP0642344A1 (en) 1995-03-15
FI945081A0 (fi) 1994-10-28
GR3023516T3 (en) 1997-08-29
ATE150310T1 (de) 1997-04-15
RU2123863C1 (ru) 1998-12-27
JPH07506366A (ja) 1995-07-13
CZ263694A3 (en) 1995-04-12
HK1002407A1 (en) 1998-08-21
DK0642344T3 (da) 1997-07-07
HU215958B (hu) 1999-03-29
NO307594B1 (no) 2000-05-02
NO944113L (no) 1994-10-28
AU674516B2 (en) 1997-01-02
FI945081A (fi) 1994-10-28
AU4115293A (en) 1993-11-29
US5599557A (en) 1997-02-04
CZ283428B6 (cs) 1998-04-15
UA27899C2 (uk) 2000-10-16
HU9403108D0 (en) 1995-02-28
NZ252433A (en) 1996-07-26
DE69309052D1 (de) 1997-04-24
CA2134467A1 (en) 1993-11-11
WO1993021923A1 (en) 1993-11-11

Similar Documents

Publication Publication Date Title
ES2099438T3 (es) Polvo seco y estable de cefalosporina hidratada para formulacion de suspension oral.
BG103518A (en) 2-(purin-9-yl)tetrahydrofuran-3,4-diol derivatives
HUT37418A (en) Process for producing new 2,2'-imino-bis/ethanol/ derivatives and pharmaceutical compositions sontaining them as active agents
ES8608864A1 (es) Un procedimiento para producir un preparado a modo de hojas
MY101791A (en) New benzimidazole derivatives
IL55274A (en) 4-(2,6-dihydroxy-4-(dimethylheptyl)phenyl)substituted 2-pinen-10-ol and pinane derivatives,their preparation and pharmaceutical compositions comprising them
IL84944A (en) Pharmaceutical compositions containing 1,2-dihydro-3h-indazolone derivatives,some new such compounds and their preparation
DE3783356D1 (de) Benzimidazolderivate, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische praeparate.
IL102814A0 (en) Pyrazine derivatives,their preparation and pharmaceutical compositions comprising them
MX9300779A (es) 3-(1h-tetrazol-5-y1)-4h-pyrido[1,2-a]pirimidina-4-onas composiciones farmaceuticas que las contienen y su preparacion de las mismas
MX9704034A (es) Derivados y composiciones de 1,1-dioxido de 2-arilcarboniloximetil-1,2,5-tiadiazolidin-3-ona substituido y metodo de uso.
HU895241D0 (en) Process for the preparation of substituted 1,3,5-triazin-trione derivatives and pharmaceutical compositions containing said compounds as active ingredient
ES8404852A1 (es) Procedimiento para preparar derivados de acidos isoquinolein-4-carboxilicos
FR2505826B1 (fr) Derives d'isoprenylamine et compositions pharmaceutiques preparees avec ces derives
DE3474024D1 (en) Contraceptive compositions based on esters of levo-norgestrel
ES8504774A1 (es) Procedimiento para preparar derivados de 2-piperacinil-quinazolina
HU9302813D0 (en) Pharmaceutical compositions containing new benzimidazole derivatives and process for preparing the active ingredients
IT1228130B (it) Derivati dell'1,1,2-trifenilpropano e dell'1,1,2-trifenilpropene, procedimento per la loro preparazione e composizioni farmaceutiche contenenti i composti
ITMI911445A1 (it) Impiego di derivati fosfolipidici per la preparazione di composizioni farmaceutiche aventi attivita' immunosoppressiva
NZ211846A (en) 2,3-diamino-2,3-didesoxyhexose derivatives and pharmaceutical compositions thereof
HUT49590A (en) Process for producing benzimidazole derivatives and pharmaceutical compositions comprising same as active ingredient
DE3264304D1 (en) Use of 2-hydroxy-3,4,4-trimethyl-cyclopent-2-ene-1-one as odorant ingredient
FR2541114B1 (fr) Compositions pharmaceutiques antifongiques utilisables par voie orale contenant de l'omoconazole
DE69215511D1 (de) Gem-diphosphonsäure-nitrosocarbamoylderivate, verfahren zu deren herstellung und sie enthaltende pharmazeutische zubereitungen
FR2567756B1 (fr) Nouvelles compositions pharmaceutiques contenant comme ingredient actif l'acetyl-10 triacetoxy-1,8,9 anthracene

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 642344

Country of ref document: ES